CiMaas receives exclusive option for the use of high affinity antibody structures in immune cells, including CAR-NK and CAR-T cells https://t.co/o3yWS0NMeb
CiMaas will be present at BIO Capital Europe 2019 in Amsterdam.
BIO Capital Europe is a meeting place for investors and life science companies.
CiMaas will present its strategy and progress at 5 PM on March 14.
CiMaas will be present at BIO Capital Europe 2019 in Amsterdam.
BIO Capital Europe is a meeting place for investors and life science companies.
CiMaas will present its strategy and progress at 5 PM on March 14.